type of report	**Current report**
number	59/2013
company	PHARMENA

July 2013 monthly report

The Management Board of Pharmena S.A. hereby presents its monthly report for July 2013.

1. Information on trends and events occurring in the Issuer's market environment

To the best knowledge of the Management Board, in July 2013 no trends or events occurred in the Issuer's market environment which could significantly influence financial results of the company.

In July 2013, Pharmena accomplished sales revenue from its dermatological cosmetics in the amount of 0.875 million PLN, which constitutes an increase by almost 100% when compared to July 2012.
In the said period, Pharmena S.A. enhanced the availability of its products and carried out marketing actions in order to increase sales profit from marketed products.

In the area of clinical trials on innovative anti-atherosclerotic medicinal product, during the period covered by this report, the following events occurred:
On 15th June 2013, the subsidiary company Cortria Corporation (USA) applied to Health Canada's Natural Health Products Directorate, for granting permission to phase II clinical trials ("Proof of Concept") of innovative anti-atherosclerosis medicinal product based on 1-MNA active substance (working name of the product TRIA-662).
It is planned, that phase II clinical trials ("Proof of Concept") will be randomised, multi-centred, placebo controlled, with total participation of at least 64 subjects (two control groups: 1-MNA, placebo, ratio: 3:1). The actual clinical trial will be preceded by a 6-week period, when 200 subjects will be subjected to controlled diet. After this time randomisation will take place, i.e. random selection of at least 64 subjects from the group of subjects subjected to the controlled diet. Randomly selected subjects who fulfil the inclusion criteria will participate in the actual clinical trial, in which 1-MNA medicinal product will be administered to them. Medicinal product will be administered 3 times a day, with a meal, for the period of 14 weeks. Key parameters of lipid profile will be controlled (i.e. TG, HDL, LDL and TC levels), inflammation (CRP, IL6) and parameters related to the safety of the medicinal product (i.e. glucose, ALT, ASP, electrocardiogram). Upon completion of the trial, a report containing trial results will be issued.
The aim of the trial is to establish the effective dose of the medicinal product and to confirm the lack of side effects in humans in higher doses. Planned time scope for the trial is 12 months from the date of obtaining permission from Health Canada market regulator. The supervisory institution will be Montreal Heart Institute, and participation of ca. 15 clinics in the trial is planned.
Conducting of phase II clinical trial is necessary for commercialisation of 1-MNA anti-atherosclerotic medicinal product project, while potential revenues on the medicinal product commercialisation may have very significant impact on financial results and market valuation of the Issuer.

In the area of works over 1-MNA dietary supplement, during the period covered by this report, the following events occurred:
On 19th July 2013, analytical research over the pilot batch of the product was concluded. The research demonstrated that the process of formulation and production of 1-MNA capsules was performed in a proper manner. The capsules conform to the specification and contain the assumed quantity of active substance 1-MNA.
The 1-MNA dietary supplement is an innovative product that has a capacity to influence the risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin which reduces the risk of atherosclerosis development.
Having successfully finalised the registration processes of 1-MNA dietary supplement as new foodstuff within the European procedure, the Issuer will commence the manufacture of 1-MNA dietary supplement and place the product on EU markets.
Introduction of innovative dietary supplement containing 1-MNA on the market may have a significant influence on the Company's revenue in the next few years.

Moreover in July 2013, Issuer's Capital Group continued its research and development work on new products and searched for new applications for active substances protected by patents and patent applications owned by the Issuer's Capital Group.

Due to the successful conclusion of public offering of series D shares (with pre-emptive rights) which took place in June 2013, the Company presented in July 2013 a summary of the subscription of series D shares. The subscription took place from 5th to 19th June 2013. 1,759,010 series D shares were allocated to 67 investors within basic subscriptions, and to 7 investors within additional subscriptions (reduction rate in additional subscriptions was 98.36%). Issue price per 1 series D share was 7.5 PLN. Costs of the issue amounted to ca. 390,000 PLN. The net amount of funds raised from the issue amounted to ca. 12.8 million PLN.
On 18th July 2013, commenced a listing of 1,759,010 (one million seven hundred fifty-nine thousand and ten) allotment certificates for series D shares on the NewConnect market. Allotment certificates for series D shares will be listed until 13th August 2013, whereas from 14th August 2013, series D shares will be listed.
On 25th July 2013, the District Court for Łódź Śródmieście in Łódź, 20th Division of the National Court Register registered the Company's share capital increase by 175,901.00 PLN (say: one hundred seventy-five thousand nine hundred and one PLN 00/100) through the issue of 1,759,010 series D shares of a nominal value of 0.10 PLN each. Therefore, after the court registration of the increase, the share capital of PHARMENA S.A. amounts to 879,505.20 PLN (say: eight hundred seventy-nine thousand five hundred and five PLN 20/100).
Also, on 25th July 2013, a court registration of changes to Articles of Association took place. The change repealed the previous wording of article 10 point 4 of Articles of Association and implemented new content thereof. The current (registered) wording of the article 10, point 4 of Articles of Association reads as follows: "Supervisory Board and shareholders representing at least 1/20 of share capital are entitled to request that specific items are put on the agenda of an oncoming General Meeting."

2. Achievement of the goals of an issue

In July 2013, Pharmena S.A. did not make any money expenditure directly on issue-related purposes. However, a subsidiary company Cortria Corporation spent in its funds on counselling services related to the preparation of application for phase II clinical trials, bioavailability testing, patent fees, production of tablets for phase II trials, as well as legal services.

3. A list of all information published by the Issuer in the form of current reports in the reporting period from 1st July 2013 to 31st July 2013.
During the period covered by this report, Pharmena S.A. published the following reports in EBI system:
• Current report no. 46/2013 of 02-07-2013 - Summary of subscription of series D shares
• Current report no. 47/2013 of 10-07-2013 - Supplement to report no 44/2013 - Appointment of the Supervisory Board for the new term of office
• Current report no. 48/2013 of 12-07-2013 - June 2013 monthly report
• Current report no. 49/2013 of 12-07-2013 - Submitting application for establishing first day of listing of allotment certificates for series D shares of Pharmena S.A. on the NewConnect market
• Current report no. 50/2013 of 16-07-2013 - Establishing the first day of listing of allotment certificates for series D shares
• Current report no. 51/2013 of 16-07-2013 - Filing to Health Canada for granting permission to phase II clinical trials of anti-atherosclerosis medicinal product 1-MN
• Current report no. 52/2013 of 22-07-2013 - Successful conclusion of analytical research over the pilot batch of 1-MNA dietary supplement
• Current report no. 53/2013 of 25-07-2013 - Court registration of share capital increase through the issue of series D shares
• Current report no. 54/2013 of 25-07-2013 - Court registration of the changes to Articles of Association

During the period covered by this report, Pharmena S.A. published the following reports in ESPI system:
• Current report no. 10/2013 of 05-07-2013 – Information on transactions in financial instruments of the Issuer
• Current report no. 11/2013 of 05-07-2013 – Information on transactions in financial instruments of the Issuer
• Current report no. 12/2013 of 09-07-2013 – Information on transactions in financial instruments of the Issuer
• Current report no. 13/2013 of 29-07-2013 - Disclosure of shareholding – decreasing of the share held by a shareholder under 10% of the total number of votes
• Current report no. 14/2013 of 31-07-2013 - Disclosure of shareholding – decreasing of the share held by a shareholder under 15% of the total number of votes
• Current report no. 15/2013 of 31-07-2013 – Information on transactions in financial instruments of the Issuer

4. Investor's calendar for August 2013
14-08-2013 – publication of Q2 2013 quarterly report
30-08-2013 - the right to dividend date
Until 14-09-2013 – publication of August 2013 monthly report

Legal basis: Resolution No. 795/2008 of the Warsaw Stock Exchange Management Board dated 31st November 2008 concerning the adoption of the codes of best practice applicable on the NewConnect market, Appendix 1, point 16.

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska - Vice President of the Board